Healio’s top retina/vitreous items this week covered a license agreement between Astellas and 4D Molecular Therapeutics as well as a review of retinal vasculitis or vascular occlusion events following treatment with brolucizumab.
Check out these items and more below.
Astellas, 4D Molecular Therapeutics enter license agreement for retinotopic vector
Astellas Pharma and 4D Molecular Therapeutics have entered into a license agreement that grants Astellas the rights to utilize 4DMT’s intravitreal retinotopic R100 vector for treating rare monogenic ophthalmic diseases. Read more.
Most